DUBLIN–(BUSINESS WIRE)–The “China Ophthalmic Service Market: Size, Trends & Forecasts (2019-2023)” report has been added to ResearchAndMarkets.com’s offering. China Ophthalmic Service Market: Size, Trends & Forecasts (2019-2023) provides analysis of the China ophthalmic service market, with detailed analysis of market size and growth, and value of the industry. The analysis includes the market by value, by outpatients, inpatients, segment and by sub-segments. Moreover, the report also
Author: Business Wire
Global Ophthalmics Partnering 2014-2019: Financial Deal Terms for Headline, Upfront and Royalty by Stage of Development – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Ophthalmics Partnering 2014-2019: Deal Trends, Players and Financials” report has been added to ResearchAndMarkets.com’s offering. Global Ophthalmics Partnering 2014 to 2019 provides the full collection of Ophthalmics disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology.
Tangible Science Launches Tangible Clean, the Ideal Multi-Purpose Solution for Tangible Hydra-PEG Coated Lenses
REDWOOD CITY, Calif.–(BUSINESS WIRE)–Tangible Science launches Tangible Clean, the ideal cleaning solution for Tangible Hydra-PEG coated gas permeable contact lenses.
Ocular Therapeutix™ Reports Election of Leslie Williams to Board of Directors
BEDFORD, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24OCUL&src=ctag" target="_blank"gt;$OCULlt;/agt; lt;a href="https://twitter.com/hashtag/OCUTX?src=hash" target=&…
UnitedHealthcare Launches National Vision Laboratory Network Relationship with Essilor Labs
MINNETONKA, Minn.–(BUSINESS WIRE)–UnitedHealthcare has launched a national vision laboratory network relationship with Essilor Labs.
Compulink Previews New User Interface for its Optometry SMART EHR at Vision Expo East
NEWBURY PARK, Calif.–(BUSINESS WIRE)–Compulink previews new User Interface for its Optometry SMART EHR at this week’s Vision Expo East.
Ocular Therapeutix™ to Host 2019 Research & Development Day
BEDFORD, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24OCUL&src=ctag" target="_blank"gt;$OCULlt;/agt; lt;a href="https://twitter.com/hashtag/OCUTX?src=hash" target=&…
EnChroma® Expands Indoor Collection of Color Blind Glasses and Adds Retail Partners
NEW YORK & BERKELEY, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/colorishere?src=hash" target="_blank"gt;#colorisherelt;/agt;–EnChroma Expands Indoor Collection of Color Blind Glasses; new cl…
Aura Biosciences to Present Interim Phase 1b/2 Clinical Data for AU-011 at the International Society of Ocular Oncology 2019 Annual Meeting
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that interim clinical data from its Phase 1b/2 clinical trial evaluating the safety and efficacy of light-a…
SEODONG Medical推出创新干眼症治疗仪器,深受海外消费者好评
韩国 釜山–(BUSINESS WIRE)–SEODONG Medical推出创新干眼症治疗仪器 NURIEYE,深受海外消费者好评
Seodong Medical Launches Globally Recognized Innovative Device for Treating Dry Eye Syndrome
BUSAN, South Korea–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/NURIEYE?src=hash" target="_blank"gt;#NURIEYElt;/agt;–Seodong Medical Launches Globally Recognized Innovative Device NURIEYE for Treating Dr…
DentalPlans.com Reminds Workers to Protect Their Eyes on The Job
PLANTATION, Fla.–(BUSINESS WIRE)–DentalPlans.com shares top eye safety tips for workers across the country in honor of Workplace Eye Wellness Month.
VisionCare, Inc. Announces Regulatory Approval of the CentraSight Treatment Program in Australia
SARATOGA, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/AMD?src=hash" target="_blank"gt;#AMDlt;/agt;–VisionCare, Inc. announced that the Australian Department of Health Therapeutic Goods Administra…
Global Amblyopia Clinical Trials Review, H2, 2018 Featuring Herantis Pharma & Santen Pharmaceutical – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Amblyopia Global Clinical Trials Review, H2, 2018″ clinical trials has been added to ResearchAndMarkets.com’s offering. Amblyopia Global Clinical Trials Review, H2, 2018” provides an overview of Amblyopia clinical trials scenario. This report provides top line data relating to the clinical trials on Amblyopia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease
Children’s Hospital Los Angeles Receives $1.6M Grant to Study Retinoblastoma
LOS ANGELES–(BUSINESS WIRE)–Retinoblastoma is a tumor of the retina that generally affects children under 5 years of age and accounts for approximately 4% of childhood cancers. If not diagnosed early, retinoblastoma may result in loss of one or both …
BioTime to Present at Oppenheimer & Co. 29th Annual Healthcare Conference on March 20, 2019
ALAMEDA, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24BTX&src=ctag" target="_blank"gt;$BTXlt;/agt; lt;a href="https://twitter.com/hashtag/AMD?src=hash" target=&quo…
Aerpio Pharmaceuticals Announces Results From TIME-2b Study of AKB-9778 in Diabetic Retinopathy
CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced top-line results from the Compa…
Acucela Signs Agreement to Develop a Compact OCT for NASA’s Deep Space Missions
SEATTLE–(BUSINESS WIRE)–Acucela Inc. (“Acucela”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today that the company signed the agreement with the Translationa…
GenSight Biologics annonce la présentation des résultats à 72 semaines de l’étude clinique de Phase III REVERSE avec GS010 au Congrès 2019 du NANOS
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée à la découverte et au développement de thérapies géniques innovantes pour le traitemen…
GenSight Biologics Announces Presentation of 72-Week Data From the REVERSE Phase III Trial of GS010 at the 45th Annual Meeting of NANOS
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative disease…